Literature DB >> 9462703

Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas.

T Pietsch1, M R Nicotra, R Fraioli, H K Wolf, M Mottolese, P G Natali.   

Abstract

Increasing experimental evidence indicates that stem-cell factor (SCF) and its cognate receptor c-Kit may participate in the growth control of various solid human malignancies. In the present study, we have extended this analysis to non-small-cell lung carcinomas (NSCLC). The results of an immunohistochemical analysis demonstrated that c-Kit/SCF are expressed by 30%/58% of adenocarcinomas, 15%/37% of squamous-cell carcinomas and by 40%/30% of undifferentiated carcinomas respectively. In 15% of primary and 18% of metastatic tumors, co-expression of the receptor and its ligand was documented. Western-blot assays of tumor extracts demonstrated that both molecules exhibit features of the normal receptor and ligand. Since biologically active SCF is physiologically present in the bloodstream, our data indicate that SCF is available to c-kit-expressing NSCLC cells via autocrine, paracrine or endocrine mechanisms. Thus activation of c-Kit in these tumors may contribute critically to their progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462703     DOI: 10.1002/(sici)1097-0215(19980119)75:2<171::aid-ijc1>3.0.co;2-r

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Expression of c-kit and p53 in non-small cell lung cancers.

Authors:  Jinyoung Yoo; Chi Hong Kim; So Hyang Song; Byoung Yong Shim; Youn Ju Jeong; Meyung Im Ahn; Sung Whan Kim; Deog Gon Cho; Min Seop Jo; Kyu Do Cho; Hong Joo Cho; Hoon-Kyo Kim
Journal:  Cancer Res Treat       Date:  2004-06-30       Impact factor: 4.679

2.  Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.

Authors:  Vera Levina; Adele Marrangoni; Tingting Wang; Simul Parikh; Yunyun Su; Ronald Herberman; Anna Lokshin; Elieser Gorelik
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

3.  Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Authors:  Faye M Johnson; B Nebiyou Bekele; Lei Feng; Ignacio Wistuba; Xi Ming Tang; Hai T Tran; Jeremy J Erasmus; Li-Ling Hwang; Naoko Takebe; George R Blumenschein; Scott M Lippman; David J Stewart
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

4.  Expression of KIT (CD117) in biphasic pulmonary blastoma. Novel data on histogenesis.

Authors:  T Hansen; F Bittinger; C Kortsik; B Wagner; C J Kirkpatrick
Journal:  Lung       Date:  2003       Impact factor: 2.584

5.  HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC).

Authors:  Anil Potti; Apar Kishor Ganti; Sascha A Tuchman; Kaley Sholes; Eric Langness; Vijay Koka; Michael Koch
Journal:  J Carcinog       Date:  2005-06-09

Review 6.  Targeted therapies and immunotherapy in non-small-cell lung cancer.

Authors:  D Cortinovis; M Abbate; P Bidoli; S Capici; S Canova
Journal:  Ecancermedicalscience       Date:  2016-06-23

7.  In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed.

Authors:  Fabian Eberle; Florian H Leinberger; Miriam F Saulich; Werner Seeger; Rita Engenhart-Cabillic; Jörg Hänze; Katja Hattar; Ekkehard Dikomey; Florentine S B Subtil
Journal:  Clin Transl Radiat Oncol       Date:  2017-02-28

Review 8.  Role of tyrosine kinases in bladder cancer progression: an overview.

Authors:  Amir Sadra Zangouei; Amir Hossein Barjasteh; Hamid Reza Rahimi; Majid Mojarrad; Meysam Moghbeli
Journal:  Cell Commun Signal       Date:  2020-08-14       Impact factor: 5.712

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.